Shiraki Kimiyasu, Mishima Mizuki, Sato Noriaki, Imoto Yasuo, Nishiwaki Kiyoji
Senri Kinran University, Suita, Osaka, 565 0873, Japan.
Department of Bioscience, School of Science and Technology, Kwansei Gakuin University, 2-1 Gakuen, Sanda, 669-1339, Japan.
Heliyon. 2024 Jul 26;10(15):e35331. doi: 10.1016/j.heliyon.2024.e35331. eCollection 2024 Aug 15.
Reproductive toxicity is one of the major concerns in drug development. Thus, we have developed its screening system using which has a life cycle of three days and similar coding genes as humans. Antiviral nucleoside analogs used for acute infections are known to cause reproductive toxicity, contraindicated for pregnant women, and are used for comparing their reproductive toxicity in and experimental animals. None of the drug treatments affected the number of offspring and the concentrations without toxicity to nematodes were consistent with no cytotoxicity or toxicity in experimental animals or humans. Favipiravir, ribavirin, molnupiravir (NHC), acyclovir, ganciclovir, zidovudine, and thalidomide significantly increased the incidence of arrested embryos but amenamevir, letermovir, and guanosine did not. RNA-dependent RNA polymerase (RdRp) inhibitors, in the order of favipiravir, ribavirin, and NHC increased the incidence of arrested embryos, possibly due to the specificity of favipiravir for RdRp and less cytotoxicity. RdRp inhibitors would impair RNA interference through RdRp expressed by telomerase reverse transcriptase during embryogenesis and cause embryo-fetal toxicity. The incidence of arrested embryos may be affected by differences in the substrate specificity of DNA polymerases and metabolism between , animals, and humans. The concordance between the results of the screening system for reproductive toxicity of antivirals in and those in experimental animals based on the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use, reproductive toxicology confirms its appropriateness as a screening system for reproductive toxicity. Favipiravir and zidovudine were the least toxic to among the antiviral drugs examined.
生殖毒性是药物研发中的主要关注点之一。因此,我们开发了一种筛选系统,该系统使用的生物具有三天的生命周期且编码基因与人类相似。用于急性感染的抗病毒核苷类似物已知会导致生殖毒性,孕妇禁用,并且用于比较它们在该生物和实验动物中的生殖毒性。没有一种药物处理影响后代数量,对线虫无毒性的浓度与在实验动物或人类中无细胞毒性或毒性一致。法匹拉韦、利巴韦林、莫努匹韦(NHC)、阿昔洛韦、更昔洛韦、齐多夫定和沙利度胺显著增加了胚胎停滞的发生率,但阿美昔韦、来特莫韦和鸟苷没有。按法匹拉韦、利巴韦林和NHC的顺序,RNA依赖性RNA聚合酶(RdRp)抑制剂增加了胚胎停滞的发生率,这可能是由于法匹拉韦对RdRp的特异性和较低的细胞毒性。RdRp抑制剂会在胚胎发生过程中通过端粒酶逆转录酶表达的RdRp损害RNA干扰,并导致胚胎-胎儿毒性。胚胎停滞的发生率可能受DNA聚合酶底物特异性以及该生物、动物和人类之间代谢差异的影响。基于人用药品注册技术国际协调理事会的抗病毒药物生殖毒性筛选系统在该生物中的结果与在实验动物中的结果之间的一致性,生殖毒理学证实了其作为生殖毒性筛选系统的适用性。在所检测的抗病毒药物中,法匹拉韦和齐多夫定对该生物的毒性最小。